Dual Anti-Platelet Therapy in Patients With Coronary Multi-Vessel Disease (DAPT-MVD)

A phase 4 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 8250 participants.

Also called NCT04624854

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; no masking; primary purpose treatment
Phase
Phase 4
Enrolled
  • 8,250 participants (enrolled count) (from the registry)
Sponsor
Registry
  • NCT NCT04624854
Other papers using this trial's data
  • Extended Dual Antiplatelet Therapy for Multivessel Coronary Artery Disease The New England journal of medicine, 2026-07-16 DOI, PubMed 42456136

Courtesy of the U.S. National Library of Medicine.

Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Countries
China (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT04624854. Randomized; no masking; primary purpose treatment. Start 2020-10-28 (actual); primary completion 2025-09-23 (actual). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Dual Anti-Platelet Therapy in Patients With Coronary Multi-Vessel Disease (DAPT-MVD)
Condition
Myocardial Ischemia
Condition
Acute Coronary Syndrome
Condition
Heart Diseases
Condition
Syndrome Heart Disease
Condition
Cardiovascular Diseases
Condition
Arteriosclerosis
Condition
Arterial Occlusive Diseases
Condition
Coronary Disease
Condition
Vascular Diseases
Intervention (Drug)
Clopidogrel and aspirin dual-antiplatelet therapy
Intervention (Drug)
Aspirin monotherapy
Lead sponsor
Harbin Medical University (class: other)
Collaborator
Chinese Society of Cardiology (class: other)
Collaborator
Lepu Medical Technology (Beijing) Co., Ltd. (class: industry)

Record details

Record id
cardio:ct-nct04624854
Content hash
898f793ae4a9c56177d7f30ef1599699cf083068ab9421afd08e112ed850cf5b